Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
McKesson
Mallinckrodt
Merck
McKinsey

Last Updated: June 27, 2022

Teva Pharms Usa Company Profile


✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for TEVA PHARMS USA, and what generic and branded alternatives to TEVA PHARMS USA drugs are available?

TEVA PHARMS USA has two hundred and three approved drugs.

There are twenty-five tentative approvals on TEVA PHARMS USA drugs.

Summary for Teva Pharms Usa
US Patents:0
Tradenames:177
Ingredients:174
NDAs:203

Drugs and US Patents for Teva Pharms Usa

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms Usa DIVALPROEX SODIUM divalproex sodium CAPSULE, DELAYED REL PELLETS;ORAL 211505-001 Nov 17, 2020 DISCN No No See Plans and Pricing See Plans and Pricing
Teva Pharms Usa OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE hydrochlorothiazide; olmesartan medoxomil TABLET;ORAL 200532-003 Apr 24, 2017 DISCN No No See Plans and Pricing See Plans and Pricing
Teva Pharms Usa DESVENLAFAXINE desvenlafaxine fumarate TABLET, EXTENDED RELEASE;ORAL 205208-001 Oct 11, 2013 DISCN No No See Plans and Pricing See Plans and Pricing
Teva Pharms Usa VECURONIUM BROMIDE vecuronium bromide INJECTABLE;INJECTION 074688-002 Aug 25, 1999 AP RX No No See Plans and Pricing See Plans and Pricing
Teva Pharms Usa DAUNORUBICIN HYDROCHLORIDE daunorubicin hydrochloride INJECTABLE;INJECTION 065035-001 Jan 24, 2000 AP RX No No See Plans and Pricing See Plans and Pricing
Teva Pharms Usa DEFERASIROX deferasirox GRANULE;ORAL 214180-002 Nov 19, 2021 AB RX No No See Plans and Pricing See Plans and Pricing
Teva Pharms Usa AMLODIPINE BESYLATE AND VALSARTAN amlodipine besylate; valsartan TABLET;ORAL 091235-003 Mar 30, 2015 DISCN No No See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Teva Pharms Usa

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-002 Feb 12, 2002 7,199,098 See Plans and Pricing
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-002 Feb 12, 2002 8,367,605 See Plans and Pricing
Teva Pharms Usa COPAXONE glatiramer acetate FOR SOLUTION;SUBCUTANEOUS 020622-001 Dec 20, 1996 6,362,161 See Plans and Pricing
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-002 Feb 12, 2002 6,362,161 See Plans and Pricing
Teva Pharms Usa COPAXONE glatiramer acetate FOR SOLUTION;SUBCUTANEOUS 020622-001 Dec 20, 1996 6,939,539 See Plans and Pricing
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-003 Jan 28, 2014 8,367,605 See Plans and Pricing
Teva Pharms Usa COPAXONE glatiramer acetate FOR SOLUTION;SUBCUTANEOUS 020622-001 Dec 20, 1996 5,981,589 See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for TEVA PHARMS USA drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 2015-06-03
➤ Subscribe Injection 40 mg/mL, 1 mL pre-filled syringe ➤ Subscribe 2014-02-26
➤ Subscribe for Injection 200 mcg/vial ➤ Subscribe 2015-05-01
➤ Subscribe Injection 40 mg/mL, 1 mL pre-filled syringe ➤ Subscribe 2014-01-29
➤ Subscribe for Injection 100 mcg/vial and 500 mcg/vial ➤ Subscribe 2015-04-14
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Harvard Business School
Colorcon
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.